The test, called the High-risk Influenza Screen Test, analyzes genetic codes immune cells release into the blood to warn of a potentially deadly infection caused by the flu virus, such as pneumonia.
The test needs one drop of a patient’s blood to predict if the patient is at-risk of developing a secondary infection. The test has a 91 percent accuracy rate, according to the research team.
The test can also be used to track the efficacy of new drugs as it measures a patient’s immune response.
The researchers detailed their findings in the European Respiratory Journal.
More articles on quality:
Depression affects nearly one-third of hospital patients, study finds
AHA urges CMS: Use only quality measures that matter
61% of pediatric nurses in poor work environments miss care, study shows
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
